and urine samples were collected before and after an intravenous drip infusion of 500 mg racemic morinidazole. Ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry revealed 10 metabolites. Morinidazole glucuronidation followed by renal excretion was the major elimination pathway, accounting for 35% of the dose. The metabolic pathway displayed regio-and stereoselectivities. Unexpectedly, the nitrogen of the morpholine ring, rather than the aliphatic hydroxyl group at the side chain, was glucuronidated to form S-morinidazole glucuronide (M8-1) and R-enantiomer glucuronide (M8-2). The plasma exposure of M8-2 was six-fold higher than that of M8-1, accounting for 22.9% and 3.96% of the parent drug exposure, respectively. Investigation of morinidazole glucuronidation 
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Introduction
Morinidazole, [R,S-1-(2-methyl-5-nitro-1H-imidazol-1-yl)-3-morpholinopropan-2-ol], a third-generation 5-nitroimidazole antimicrobial, is currently in clinical development as a racemic mixture for the treatment of amoebiasis, trichomoniasis, and anaerobic bacterial infections (Lv, 2008) . The bactericidal activity of morinidazole, which is similar to that of metronidazole (the prototype nitroimidazole antimicrobial), depends on the formation of a redox intermediate metabolite in the bacterium which causes DNA strand breakage, inhibits repair, and ultimately leads to cell death (Müller, 1983; Kedderis et al., 1989; Lamp et al., 1999) . A previous study
showed that morinidazole exhibited greater activity against trichomoniasis and amoebiasis but had less toxicity than metronidazole in mice (Lv, 2008) . However, the difference of pharmacological acitivity of R-and S-morinidazole is not reported.
During clinical studies, metabolism investigations play a crucial role in promoting the safe use of a drug, including predicating the potential drug-drug interaction as well as dosing adjustments. However, the metabolism of morinidazole has not been previously reported. In our preliminary clinical pharmacokinetic study, two morinidazole glucuronides were detected as the main metabolites in human urine and plasma after an intravenous drip infusion. Morinidazole contains an aliphatic hydroxyl, an imidazole ring and a morpholine ring, all of which are potential sites for conjugation with glucuronic acid. Enzymatic hydrolysis experiments demonstrated that both glucuronides were resistant to hydrolysis by β -glucuronidase from Helix pomatia (in pH 5 and pH 7.4 buffers) but susceptible to hydrolysis by β -glucuronidase from Escherichia coli at pH 7.4, indicating that the glucuronides may be N + -glucuronides and not O-glucuronides (Kowalczyk et al., 2000) . Selective glucuronidation at an aliphatic tertiary amine group in the presence of a hydroxyl
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5 group would be an unusual metabolic pathway.
The objectives of the current study are (1) to investigate the metabolism of morinidazole in humans after an intravenous drip infusion administration by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS); (2) to characterize pharmacokinetics and excretion profiles of morinidazole and its major metabolites in humans (3) to identify UGT(s) responsible for morinidazole glucuronidation using HLMs and UGTs. The paper also attempts to address the stereoselectivity in the sulfation of morinidazole by using cryopreserved human hepatocytes.
This article has not been copyedited and formatted. The final version may differ from this version. 2 and 8 h), and equal volumes (100 μl) from all subject were combined. Urine samples (0-24 h) were pooled across all subjects by combining volumes proportional to the total volume excreted from each subject for each collection interval.
Acetonitrile (200 µl) was added to a 100 µl aliquot of pooled plasma or urine sample.
The mixture was vortex-mixed and centrifuged at 11,000×g for 5 min. The supernatant was transferred into a clean plastic tube and evaporated to dryness in a Turbo Vap evaporator (Zymark Corp., Hopkinton, MA, USA) under a nitrogen stream at 40°C. The residue was reconstituted in 100 µl of the mixture of 10 mM ammonium formate and methanol containing 10 m M ammonium formate (10:90, v/v). A 10 μ l aliquot of the reconstituted extract was injected into the UPLC-UV/Q-TOF MS system.
For enzymatic incubation, 100 μ l β -glucuronidase (2,000 units, at both pH 7.4 and This article has not been copyedited and formatted. The final version may differ from this version. Nitrogen and argon were used as API and collision gas, respectively. The capillary and cone voltages were set at 3000 and 40 V, respectively. The desolvation gas (nitrogen) was set to 800 l/h at a temperature of 350°C, and the source temperature was 100°C. Data from 80 to 1000 Da were acquired and corrected during acquisition using an external reference (LockSpray TM ) comprised of 400 ng/ml leucine encephalin (m/z 556.2771) infused at 5 μ l/min. An M S E scan function was programmed with two independent collision energies (CE). At low collision energy, the transfer and trap CEs were 2 and 3 eV, respectively. At high collision energy, the transfer was 10 eV and trap CE ramped from 10 to 20 eV. Data acquired in th is (Zhang et al., 2008) . Fragmentations were proposed based on plausible deprotonation sites, subsequent isomerization, electron species, and bond saturation using the Mass Frontier 7.0 software (Thermo Fisher Scientific Inc., San Jose, CA, USA). The corresponding precursor and fragmentation data for each detected metabolite were available from the mass spectra at low and high collision energies, respectively. The elemental composition of each metabolite and its structure were determined using the MetaboLynx TM software. 
Preparation of the Major Metabolites from Human
Quantification of Morinidazole and Its Four Metabolites in Human Plasma
and Urine. The concentrations of morinidazole and its major metabolites M4-1, M7, M8-1, and M8-2 in individual human plasma and urine samples were simultaneously determined by a sensitive and rapid LC-MS/MS method, which was validated according to the FDA guideline and the Crystal City III white paper (Viswanathan et al., 2007) , including selectivity, linearity, precision and accuracy, matrix effect, recovery, stability and incurred sample reanalysis. In brief, after acetonitrile-induced protein precipitation of each plasma or urine sample, the analytes and internal standard (metronidazole) were separated on a Synergi™ 4 µm Hydro-RP C 18 column using a gradient elution program. The HPLC system consisted of two LC-20AD pumps and a SILHTA autosampler (Shimadzu, Kyoto, Japan), which was interfaced to an API 4000 triple quadrupole mass spectrometer (Applied Biosystems, Concord, Ontario, Canada). Positive electrospray ionization was employed as the ionization source. The analytes and the internal standard were monitored by multiple reaction monitoring with transitions that were specific for each analyte. Calibration curves for morinidazole and its major metabolites were fitted via linear weighted (1/x 2 ) regression. The standard curve ranges were 10.0-12,000 ng/ml for morinidazole, 1.00-200 ng/ml for M4-1, 2.50-500 ng/ml for M7, 3.00-600 ng/ml for M8-1, and 10.0-3000 ng/ml for M8-2 in plasma. The standard curve ranges were 400-200000 ng/ml for morinidazole, 40.0-20000 ng/ml for M4-1, 100-50000 ng/ml for M7, 240-120000 ng/ml for M8-1, and 400-200000 ng/ml for M8-2 in urine.
Pharmacokinetic Analysis. The pharmacokinetic parameters were determined by non-compartmental methods using WinNonlin (V5.3, Pharsight, Mountain View, CA, USA). The peak concentration (C max ) and the time to reach it (T max ) were taken alamethicin, and 50 μM morinidazole with 1 mg/ml HLMs. After pre-incubation at 37°C for 5 min, the reactions were initiated by the addition of UDP-glucuronic acid.
Reactions were allowed to proceed for 1 h at 37°C and terminated with an equal volume of ice-cold acetonitrile. Incubations in the presence of morinidazole at 0 min served as the negative controls. Each incubation was performed in duplicate.
To determine the UGT enzyme(s) involved in the N + -glucuronidation of morinidazole, the assay conditions described above were used with 12 commercially available recombinant UGT enzymes, namely, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, Niflumic acid is reportedly an inhibitor of UGT1A9 (Vietri et al., 2002; Miner et al., 2011) . In the present study, niflumic acid was dissolved in DMSO, and its concentrations in the reaction mixture were adjusted to 2.50 and 10.0 μM. The morinidazole concentration was set at 50 μM. The other assay conditions were similar to those described above. One group without inhibitor but containing the same 
Investigation of Stereoselectivity in the Sulfation of Morinidazole in Human
Hepatocytes. R-and S-morinidazole (at 50 and 500 μ M) were incubated with human hepatocytes (0.8 million cells/ml) in William's E medium at 37°C for 2 h, respectively. respectively. Therefore, M2 was identified as the morpholine ring-opened morinidazole (Fig. 3) . suggested that the site of biotranformtion was located on morpholine N-methylene moiety. In the product ion spectrum of M5, the fragment ion at m/z 100.074 was also observed. Its element composition was C 5 H 10 NO + , which is the same as that of the fragment ion at m/z 100.074 from the parent drug. But the structural formulas of the two fragment ions were different, as it was difficult to los e simultaneously two oxygen atoms from the structure by LC-MS analysis. As a result, the fragment ion was proposed to be derived from the opening of the morpholine ring (Fig. 3F ).
According to the high resolution MS data, the structure of M5 was proposed as carboxylic acid metabolite formed by oxidative opening of the morpholine ring (Fig.   3F ). The exact structure of M5 needs to be further characterized. (Fig. 5) . The M8 compounds were assumed as N-glucuronides based on a previous report (Kowalczyk et al., 2000) focusing on the enzymatic hydrolysis of N + -glucuronide metabolites of drugs with an aliphatic tertiary amine.
The unequivocal identification of the metabolite is facilitated by the availability of an authentic synthetic sample. The authentic standards of the major metabolites M8-1 and M8-2 were prepared from the postdose human urine samples. NMR spectral data S3-S5). These results were in accordance with those reported for N + -glucuronide metabolites (Seaton et al., 1993; Hawes, 1998) , suggesting that glucuronic acid was introduced into the nitrogen atom of the morpholine ring to generate two N + -glucuronide metabolites of morinidazole. Considering that the parent drug used in the present study was a racemic mixture, M8-1 and M8-2 were therefore proposed as C-2′ epimers; the stereochemistry at C-2′ should be discussed. Therefore, Nuclear
Overhauser effect spectroscopy (NOESY) experiments were performed for M8-1 and Fig. S9 ).
Pharmacokinetics and Renal Elimination of Morinidazole.
After an intravenous drip infusion of 500 mg morinidazole to 12 healthy subjects, the concentrations of the parent drug and the four metabolites (M4-1, M7, M8-1, and M8-2) in human plasma and urine were quantified by a v alidated LC-MS/MS method. The mean plasma concentration versus time profiles for morinidazole, M4-1, M7, M8-1 and M8-2 are shown in Fig. 6 a nd the main pharmacokinetic parameters are presented in Table 1 .
The AUC 0-t values of morinidazole, M4-1, M7, M8-1 and M8-2 were 74866, 612, 1702, 2965 and 17164 ng·h/ml, respectively. The primary metabolites were glucuronides M8-1 and M8-2, whose plasma exposures were approximately 3.96%
and 22.9% of the parent drug exposure. The t 1/2 values of parent drug and M4-1, M7, M8-1 were similar (about 6-7 h), whereas that of M8-2 was shorter (4.2 h).
The amount of morinidazole and identified metabolites accounted for 71% of the (Table 2 and Fig. S10 ). In HLMs, the apparent K m , V max , and Cl int values were 11.3 mM, 111 pmol/min/mg protein, and 0.010 μl/min/mg protein for M8-1, and 15.1 mM, 1660 pmol/min/mg protein, and 0.110 μl/min/mg protein for M8-2, respectively. The K m /V max value of M8-2 formation was approximately 11.2-fold higher than that of M8-1.
For UGT1A9, the K m values for R-and S-morinidazole glucuronidation were calculated as 3.29 and 2.95 mM, respectively. The V max value of R-morinidazole glucuronidation was markedly higher than that of the S-isomer, which was similar to the results in HLMs. All data for N + -glucuronidation showed great similarity to those in HLMs and in the recombinant UGT1A9 incubation systems and supported the conclusion that N + -glucuronidation of morinidazole was mainly catalyzed by UGT1A9. Both HLMs and UGT1A9 showed a preference for M8-2 formation.
Elucidation of the Stereoselectivity in Sulfation of Morinidazole. To investigate
This article has not been copyedited and formatted. The final version may differ from this version. LC-MS/MS system in the multiple reaction monitoring mode. The peak area ratio for S-/R-morinidazole sulfate was about 50 (Fig. 9) . The results indicated that sulfation of morinidazole showed a large preference for the S-enantiomer.
In Vitro Metabolism of Mornidazole to Metabolites M1 and M6. Denitrated metabolite M1 was observed, abeit to a minor extent, after incubation of morinidazole with NADPH-supplemented pooled S9 fractions. M1 was not formed in HLMs incubations and in control experiments lacking NADPH in the incubation mixture (Fig. 10) . The results indicated that formation of denitrated metabolite was catalyzed by cytosolic enzymes and NADPH-dependent. Cysteine conjugate M6 was detected in the HLMs incubations and control incubations, and the amount of M6 in e ach incubation was similar. As a result, a conclusion was made that formation of M6 was independent of microsomal enzyme and NADPH. To further investigate whether M6 was a metabolite or it was an in vitro artifact, morinidazole (50 μM) was incubated in fresh pooled human urine for 4 h at 37°C or room temperature. As a result, no M6 was observed, indicating that cysteine conjugate M6 was not produced during sample storage or processing.
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Discussion
In the present study, the metabolism pharmacokinetics and excretion of morinidazole were investigated in humans. A total of 10 metabolites were detected after intravenous drip infusion administration of 500 mg morinidazole (Figs. 2 and 4) .
In plasma, the parent compound was the major circulating component. M8-1, M8-2 and M7 were the primary metabolites. Approximately 70% of the intravenous dose was recovered in urine, with 21.2% as the unchanged morinidazole, 6.6% as M8-1, 28.4% as M8-2, and 13.0% as M7.
Compared with metronidazole, morinidazole contains a morpholine ring in th e side chain. The biotransformation of morinidazole was compared with that of metronidazole. The main metabolic pathways of metronidazole in humans were hydroxylation, oxidation, O-glucuronidation, and sulfation (Stambaugh et al., 1967; O'Keefe et al., 1982; Thomsen et al., 1995) . Morinidazole shared some common metabolic pathways with metronidazole, such as hydroxylation at the 2-methyl group of the imidazole ring and sulfation at the hydroxyl group of the side chain. However, the major metabolic reactions of morinidazole occurred on the morpholine ring, including carbonylation, N-oxidation, and N + -glucuronidation.
The two unusual and minor metabolites M6 and M1 were detected in human urine.
The in vitro studies demonstrated that the formation of M6 was independent on the microsomes enzymes or NADPH. Under neutral aqueous conditions, morinidazole could react with cysteine by S N 2 reaction and the nitro group was substituted by cysteine. The similar reaction has been reported for ronidazole and dimetridazole (Giard et al., 1993) . After incubating morinidazole with HLMs and S9 fractions, M1
was detected only in NADPH-fortified S9 incubations, indicating that cytosolic enzyme was involved in this metabolic pathway. Generally, O-glucuronidation was considered to be preferentially formed over N-glucuronidation (Franklin et al., 1998; Sorich et al., 2006) . However, for drugs possessing a hydroxyl group as well as an aliphatic tertiary amine, the observed sites of glucuronidation were difficult to rationalize. Some drugs (such as morphine) in which glucuronidation occurred only at the hydroxyl group have been reported (Brunk et al., 1974; Coffman et al., 1997) , and some, such as 10-hydroxylated amitriptyline and trans-4-hydroxytamoxifen, exhibited glucuronidation at both groups (Breyer-Pfaff et al., 1990; Ogura et al., 2006) . In the present study, glucuronidation of morinidazole exhibited high regioselectivity, and no O-glucuronide metabolite was observed in vivo and in vitro. To the best of our knowledge, this phenomenon has not been previously reported. In further investigation, we found that another drug, henatinib, contains the same 3-morpholinopropan-2-ol moiety in its structure, but only After an intravenous drip infusion administration of 500 mg morinidazole, the plasma exposure of M8-2 was six-fold higher than that of M8-1, and the cumulative amount of M8-2 excreted in human urine was much higher than that of M8-1, with a ratio of 4.3:1. These results suggested that the formation of M8-2 is preferred over (Fig. 8) .
Considering that UGT1A9 was mainly expressed in the liver and kidney and that 2B17 was mainly found in the gastrointestinal tract (Kaivosaari et al., 2011) , the results indicated that the N + -glucuronidation of both S-and R-morinidazole in humans were mainly catalyzed by UGT1A9. The K m values of M8-1 and M8-2 formation by UGT1A9 were 3.3 and 3.0 mM, respectively, which were lower than those by HLMs (11.3 and 15.1 mM). Differences in the glucuronidation K m values between recombinant UGT1A9 and HLMs had been previously observed and were probably due to protein-protein interaction (Omura et al., 2007; Fujiwara et al., 2007) .
Generally, UGT1A4 was considered as an enzyme that specialized in N-glucuronidation, particularly catalyzing the conjugation of tertiary amines to quaternary N-glucuronides (Green et al., 1995; Green and Tephly, 1996; Green et al. 1998 ). Later, UGT1A3 and UGT2B10 were also found to play important roles in the N + -glucuronidation reactions of some aliphatic tertiary amines (Hawes, 1998; Zhou et al., 2010; Kaivosaari et al., 2011) . In the present study, among the 12 commercially available UGTs, only UGT1A9 was responsible for the N + -glucuronidation of the aliphatic tertiary amine of morinidazole. These results indicated that UGT1A9 was a newly identified UGT isoform involved in the N + -glucuronidation of drugs containing tertiary aliphatic amine.
In summary, the metabolism, pharmacokinetics and excretion of morinidazole in humans were investigated after an intravenous drip infusion administration.
Morinidazole undergoes extensive metabolism, including N-oxidation, hydroxylation,
